Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy

Immunoglobulin A Clinical Trial

Official title:

Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02912520
• Other study ID #: ORV001
• Status: Completed
• Phase: N/A
• First received: September 13, 2016
• Last updated: April 23, 2017
• Start date: June 2016
• Est. completion date: April 23, 2017

Study information

• Verified date: April 2017
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Investigators hypothesize that Immunoglobine (Ig) production is influenced by the microbiota of the gut. Investigators will compare microbiota-dependent Ig production in the bronchoalveolar lavage fluid of patients with and without antibiotic therapy in order to detect significant differences.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 23, 2017
• Est. primary completion date: April 23, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• endotracheal intubation

• antibiotic therapy for 2 weeks OR no antibiotic therapy for at least 3 months

Exclusion Criteria:

• active infection

• pregnancy

• immunodeficiency

Related Conditions & MeSH terms

• Immunoglobulin A

Intervention

Drug:
• Anti-Bacterial Agents
administration of any antibiotic substance(s) over the course of 2 weeks

Locations

Country	Name	City	State
Austria	Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

References & Publications (1)

Hoogkamp-Korstanje JA, de Koning J, Heesemann J, Festen JJ, Houtman PM, van Oyen PL. Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy. Infection. 1992 Mar-Apr;20(2):53-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IgA levels in the bronchoalveolar lavage fluid		2 weeks of ICU stay
Secondary	number of detected bacterial, viral, and fungal infections per patient		through study completion, an average of 2 months